目的 探讨复方万年青胶囊联合ECF方案（表阿霉素、顺铂、氟尿嘧啶）治疗晚期胃癌的临床疗效。方法 选取2017年2月-2018年3月上海中医药大学附属曙光医院和成都市西区医院收治的120例晚期胃癌患者为研究对象，采用随机数字表法分为对照组和治疗组，每组各60例。对照组采用ECF方案，第1天静脉注射盐酸表柔比星注射液50 mg/m²；第1天静脉滴注顺铂60 mg/m²；静脉滴注注射用氟尿嘧啶200 mg/m²，1次/d。治疗组在对照组的基础上口服复方万年青胶囊，3粒/次，3次/d。21 d为1个周期，两组患者治疗3个周期。观察两组的临床疗效，比较两组的QOL-C30评分、血清肿瘤标记物、不良反应、一年生存率。结果 治疗后，对照组和治疗组的临床有效率分别为33.33%、51.67%，对照组和治疗组的疾病控制率分别为71.67%、95.00%，两组比较差异有统计学意义（P<0.05）。治疗后，治疗组QOL-C30评分显著升高，血清癌胚抗原（CEA）、糖链抗原199（CA199）、糖链抗原724（CA724）水平均显著降低，同组治疗前后比较差异具有统计学意义（P<0.05）；且治疗组QOL-C30评分、血清肿瘤标记物水平明显优于对照组，两组比较差异具有统计学意义（P<0.05）。治疗后，治疗组患者治疗组患者肝功能损伤、肾功能损伤、胃肠道反应、骨髓抑制的不良反应发生情况均低于对照组，两组比较差异具有统计学意义（P<0.05）。在一年时间内，治疗组的生存率明显高于对照组，两组比较差异有统计学意义（P<0.05）。结论 复方万年青胶囊联合ECF方案治疗晚期胃癌具有较好的临床疗效，可改善患者生活质量，降低肿瘤标志物水平，提高一年生存率，具有一定临床推广应用价值。

Objective To investigate the clinical efficacy of Compound Wannianqing Capsules combined with ECF chemotherapy scheme in treatment of advanced gastric cancer. Methods Patients (120 cases) with advanced gastric cancer in Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine and Chengdu Western Hospital from February 2017 to March 2018 were randomly divided into control and treatment groups, and each group had 60 cases. Patients in the control group were given ECF chemotherapy scheme. Patients were iv administered with Epirubicin Hydrochloride Injection 50 mg/m²on the first day, and were also iv administered with Cisplatin Injection 60 mg/m²on the first day. And patients were iv administered with Fluorouracil for injection 200 mg/m², once daily. Patients in the treatment group were po administered with Compound Wannianqing Capsules on the basis of the control group, 3 grains/time, three times daily. A course had 21 d, and patients in two groups were treated for 3 courses. After treatment, the clinical efficacies were evaluated, and QOL-C30 scores, serum tumor markers, adverse reactions, and one-year survival rate in two groups were compared. Results After treatment, the clinical effective rates in the control and treatment groups were 33.33% and 51.67%, respectively, and the disease control rates in the control and treatment groups were 71.67% and 95.00%, respectively, and there was difference between two groups (P<0.05). After treatment, QOL-C30 scores in two groups were significantly increased, but the levels of CEA, CA199, and CA724 in two groups were significantly decreased, and the difference was statistically significant in the same group (P<0.05). And the observational indexes in the treatment group were significantly better than those in the control group (P<0.05). After treatment, liver function damage, kidney function damage, gastrointestinal reaction, and bone marrow suppression in the treatment group were lower than those in the control group, and there was difference between two groups (P<0.05). Within a year, the survival rate in the treatment group was significantly higher than that in the control group, and there was difference between two groups (P<0.05). Conclusion Compound Wannianqing Capsules combined with ECF chemotherapy scheme has clinical curative effect in treatment of advanced gastric cancer, can improve the quality of life of patients, reduce the level of tumor markers, and improve one-year survival rate, which has a certain clinical application value.